Do analysts rate SYPR or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sypris Solutions 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate VTSI or MYNZ?

VirTra presently has a consensus price target of $5.00, suggesting a potential upside of 89.39%. Given VirTra's stronger consensus rating and higher possible upside, research analysts clearly believe VirTra is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VirTra 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, VTSI or MYNZ?

VirTra has higher revenue and earnings than Mainz Biomed. VirTra is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VirTra $22.40M 1.33 $260K -$0.26 N/A Mainz Biomed $659.94K 15.38 -$21.65M -$65.60 N/A

Do analysts recommend MYNZ or ZENA?

ZenaTech has a consensus target price of $4.50, suggesting a potential upside of 312.84%. Given ZenaTech's stronger consensus rating and higher probable upside, analysts plainly believe ZenaTech is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ZenaTech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is MYNZ or ZENA more profitable?

Mainz Biomed has a net margin of 0.00% compared to ZenaTech's net margin of -306.35%. Mainz Biomed's return on equity of 0.00% beat ZenaTech's return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A ZenaTech -306.35% -3,081.41% -76.55%

Do analysts recommend XTIA or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTI Aerospace 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend MYNZ or EURK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Eureka Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, MYNZ or EURK?

Eureka Acquisition has lower revenue, but higher earnings than Mainz Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 15.38 -$21.65M -$65.60 N/A Eureka Acquisition N/A N/A N/A N/A N/A

Is MYNZ or EURK more profitable?

Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Eureka Acquisition N/A N/A N/A

Mainz Biomed (MYNZ) Competitors

$1.12 +0.09 (+8.74%)

As of 10/13/2026

Compare

MYNZ vs. SYPR, VTSI, ZENA, XTIA, and EURK

Should you buy Mainz Biomed stock or one of its competitors? Mainz Biomed's main competitors and comparable companies include Sypris Solutions (SYPR), VirTra (VTSI), ZenaTech (ZENA), XTI Aerospace (XTIA), and Eureka Acquisition (EURK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "aerospace & defense" industry.

How does Mainz Biomed compare to Sypris Solutions?

Sypris Solutions (NASDAQ:SYPR) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Sypris Solutions has higher revenue and earnings than Mainz Biomed. Sypris Solutions is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sypris Solutions	$119.89M	0.35	-$6.34M	-$0.47	N/A
Mainz Biomed	$659.94K	15.38	-$21.65M	-$65.60	N/A

In the previous week, Sypris Solutions had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Sypris Solutions and 0 mentions for Mainz Biomed. Sypris Solutions' average media sentiment score of 1.22 beat Mainz Biomed's score of 0.00 indicating that Sypris Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
Sypris Solutions	Positive
Mainz Biomed	Neutral

44.7% of Sypris Solutions shares are held by institutional investors. 47.9% of Sypris Solutions shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sypris Solutions has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Mainz Biomed has a net margin of 0.00% compared to Sypris Solutions' net margin of -9.23%. Mainz Biomed's return on equity of 0.00% beat Sypris Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sypris Solutions	-9.23%	-67.14%	-9.87%
Mainz Biomed	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sypris Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Sypris Solutions beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

How does Mainz Biomed compare to VirTra?

VirTra (NASDAQ:VTSI) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

VirTra presently has a consensus price target of $5.00, suggesting a potential upside of 89.39%. Given VirTra's stronger consensus rating and higher possible upside, research analysts clearly believe VirTra is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VirTra	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

14.7% of VirTra shares are held by institutional investors. 3.5% of VirTra shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mainz Biomed has a net margin of 0.00% compared to VirTra's net margin of -17.04%. Mainz Biomed's return on equity of 0.00% beat VirTra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VirTra	-17.04%	-6.59%	-4.57%
Mainz Biomed	N/A	N/A	N/A

VirTra has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

VirTra has higher revenue and earnings than Mainz Biomed. VirTra is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VirTra	$22.40M	1.33	$260K	-$0.26	N/A
Mainz Biomed	$659.94K	15.38	-$21.65M	-$65.60	N/A

In the previous week, VirTra had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for VirTra and 0 mentions for Mainz Biomed. VirTra's average media sentiment score of 0.34 beat Mainz Biomed's score of 0.00 indicating that VirTra is being referred to more favorably in the media.

Company	Overall Sentiment
VirTra	Neutral
Mainz Biomed	Neutral

Summary

VirTra beats Mainz Biomed on 10 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to ZenaTech?

Mainz Biomed (NASDAQ:MYNZ) and ZenaTech (NASDAQ:ZENA) are both small-cap industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, ZenaTech had 16 more articles in the media than Mainz Biomed. MarketBeat recorded 16 mentions for ZenaTech and 0 mentions for Mainz Biomed. ZenaTech's average media sentiment score of 0.75 beat Mainz Biomed's score of 0.00 indicating that ZenaTech is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
ZenaTech	Positive

Mainz Biomed has higher earnings, but lower revenue than ZenaTech. ZenaTech is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	15.38	-$21.65M	-$65.60	N/A
ZenaTech	$9.24M	2.65	-$32.36M	-$1.48	N/A

Mainz Biomed has a net margin of 0.00% compared to ZenaTech's net margin of -306.35%. Mainz Biomed's return on equity of 0.00% beat ZenaTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
ZenaTech	-306.35%	-3,081.41%	-76.55%

Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, ZenaTech has a beta of 7.34, indicating that its share price is 634% more volatile than the broader market.

ZenaTech has a consensus target price of $4.50, suggesting a potential upside of 312.84%. Given ZenaTech's stronger consensus rating and higher probable upside, analysts plainly believe ZenaTech is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ZenaTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

ZenaTech beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

How does Mainz Biomed compare to XTI Aerospace?

XTI Aerospace (NASDAQ:XTIA) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

11.7% of XTI Aerospace shares are owned by institutional investors. 7.4% of XTI Aerospace shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, XTI Aerospace had 14 more articles in the media than Mainz Biomed. MarketBeat recorded 14 mentions for XTI Aerospace and 0 mentions for Mainz Biomed. XTI Aerospace's average media sentiment score of 0.12 beat Mainz Biomed's score of 0.00 indicating that XTI Aerospace is being referred to more favorably in the media.

Company	Overall Sentiment
XTI Aerospace	Neutral
Mainz Biomed	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTI Aerospace	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed has lower revenue, but higher earnings than XTI Aerospace. XTI Aerospace is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTI Aerospace	$22.49M	1.33	-$68.76M	-$5.20	N/A
Mainz Biomed	$659.94K	15.38	-$21.65M	-$65.60	N/A

XTI Aerospace has a beta of 4.85, suggesting that its stock price is 385% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Mainz Biomed has a net margin of 0.00% compared to XTI Aerospace's net margin of -171.13%. Mainz Biomed's return on equity of 0.00% beat XTI Aerospace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTI Aerospace	-171.13%	-2,044.78%	-105.02%
Mainz Biomed	N/A	N/A	N/A

Summary

XTI Aerospace beats Mainz Biomed on 8 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to Eureka Acquisition?

Mainz Biomed (NASDAQ:MYNZ) and Eureka Acquisition (NASDAQ:EURK) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Eureka Acquisition	N/A	N/A	N/A

Eureka Acquisition has lower revenue, but higher earnings than Mainz Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	15.38	-$21.65M	-$65.60	N/A
Eureka Acquisition	N/A	N/A	N/A	N/A	N/A

Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Eureka Acquisition has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Eureka Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Eureka Acquisition had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Eureka Acquisition and 0 mentions for Mainz Biomed. Eureka Acquisition's average media sentiment score of 0.41 beat Mainz Biomed's score of 0.00 indicating that Eureka Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
Eureka Acquisition	Neutral

Summary

Mainz Biomed beats Eureka Acquisition on 3 of the 5 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYNZ vs. The Competition

Export

Metric	Mainz Biomed	Aerospace & Defense Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$10.15M	$19.61B	$10.09B	$13.18B
Dividend Yield	N/A	1.71%	96.63%	19.59%
P/E Ratio	-0.02	25.60	24.00	21.16
Price / Sales	15.38	108.33	274.90	66.59
Price / Cash	N/A	24.83	23.84	52.75
Price / Book	0.43	6.62	4.65	5.92
Net Income	-$21.65M	$563.23M	$614.62M	$380.90M
7 Day Performance	-21.68%	-4.43%	-2.16%	-3.90%
1 Month Performance	-15.15%	-9.48%	-3.68%	-6.42%
1 Year Performance	-24.32%	-9.28%	-0.22%	-6.02%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYNZ Mainz Biomed	N/A	$1.12 +8.7%	N/A	-27.3%	$10.15M	$659.94K	N/A	30
SYPR Sypris Solutions	0.9695 of 5 stars	$1.94 +6.6%	N/A	-22.1%	$44.67M	$115.11M	N/A	548	News Coverage
VTSI VirTra	3.5673 of 5 stars	$2.76 -2.8%	$5.00 +81.2%	-56.7%	$31.24M	$17.50M	N/A	94	Gap Up
ZENA ZenaTech	2.5062 of 5 stars	$1.30 +1.6%	$4.50 +246.2%	-83.7%	$29.25M	$9.24M	N/A	17
XTIA XTI Aerospace	0.4334 of 5 stars	$0.72 -1.9%	N/A	-48.3%	$27.85M	$22.49M	N/A	12	Trending News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYNZ) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (MYNZ) Competitors

MYNZ vs. SYPR, VTSI, ZENA, XTIA, and EURK

How does Mainz Biomed compare to Sypris Solutions?

Summary

How does Mainz Biomed compare to VirTra?

Summary

How does Mainz Biomed compare to ZenaTech?

Summary

How does Mainz Biomed compare to XTI Aerospace?

Summary

How does Mainz Biomed compare to Eureka Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (MYNZ) Competitors

MYNZ vs. SYPR, VTSI, ZENA, XTIA, and EURK

How does Mainz Biomed compare to Sypris Solutions?

Which has stronger earnings & valuation, SYPR or MYNZ?

Does the media prefer SYPR or MYNZ?

Do institutionals and insiders have more ownership in SYPR or MYNZ?

Which has more risk & volatility, SYPR or MYNZ?

Is SYPR or MYNZ more profitable?

Do analysts rate SYPR or MYNZ?

Summary

How does Mainz Biomed compare to VirTra?

Do analysts rate VTSI or MYNZ?

Do insiders and institutionals have more ownership in VTSI or MYNZ?

Is VTSI or MYNZ more profitable?

Which has more volatility & risk, VTSI or MYNZ?

Which has better valuation & earnings, VTSI or MYNZ?

Does the media favor VTSI or MYNZ?

Summary

How does Mainz Biomed compare to ZenaTech?

Does the media refer more to MYNZ or ZENA?

Which has higher earnings and valuation, MYNZ or ZENA?

Is MYNZ or ZENA more profitable?

Which has more risk & volatility, MYNZ or ZENA?

Do analysts recommend MYNZ or ZENA?

Summary

How does Mainz Biomed compare to XTI Aerospace?

Do institutionals and insiders hold more shares of XTIA or MYNZ?

Does the media prefer XTIA or MYNZ?

Do analysts recommend XTIA or MYNZ?

Which has better earnings & valuation, XTIA or MYNZ?

Which has more volatility and risk, XTIA or MYNZ?

Is XTIA or MYNZ more profitable?

Summary

How does Mainz Biomed compare to Eureka Acquisition?

Is MYNZ or EURK more profitable?

Which has stronger valuation & earnings, MYNZ or EURK?

Which has more volatility & risk, MYNZ or EURK?

Do analysts recommend MYNZ or EURK?

Does the media refer more to MYNZ or EURK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools